Trials / Completed
CompletedNCT04252287
A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
Canagliflozin: Impact on Health Status, Quality of Life, and Functional Status in Heart Failure
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 476 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the superiority of the effectiveness of canagliflozin 100 milligram (mg) daily versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Canagliflozin 100 mg | Participants will receive 100 mg immediate-release, over-encapsulated tablets (as a capsule) orally once daily. |
| DRUG | Placebo | Participants will receive matching placebo capsules orally once daily. |
Timeline
- Start date
- 2020-03-10
- Primary completion
- 2021-11-09
- Completion
- 2021-11-09
- First posted
- 2020-02-05
- Last updated
- 2025-03-30
- Results posted
- 2023-01-12
Locations
18 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04252287. Inclusion in this directory is not an endorsement.